Prostate cancer drug 'too expensive for NHS'
A chemotherapy drug that extends the lives of men with advanced prostate cancer is too expensive for use on the NHS, according to draft guidance.
The National Institute for Health and Clinical Excellence (Nice) said cabazitaxel, in combination with prednisone or prednisolone, was not cost-effective as a second line treatment after hormone therapy.
The drug has been shown to extend the lives of men with advanced prostate cancer by around 10 weeks.
Officials in Northern Ireland make their own assessment on whether a drug will be made available to patients here after Nice issues its guidance.